September 16, 2022
Hepatologist Naim Alkhouri and Endocrinologist Scott Isaacs join Ken Cusi and Roger Green to discuss drug choices prescribers can make TODAY for patients with Type 2 Diabetes Mellitus and obesity that have positive impact on Fatty Liver disease.
Every week, a global community of Fatty Liver Disease stakeholders comes together to explore the most important challenges in diagnosing, treating, and developing medications for patients with Fatty Liver Diseases.
Join hepatology researcher and Key Opinion Leader Dr. Stephen Harrison, liver wellness advocate Louise Campbell MSc AP., Forecasting and Pricing guru Roger Green, M.B.A., and their weekly guests as they discuss these issues from their own unique perspectives on the Surfing the NASH Tsunami podcast.
Surfers Roger Green, Jörn Schattenberg and Louise Campbell embark on their first exclusive discussion together in a while without any guest panelists. After several weeks of attending and reviewing conferences, the trio take the opportunity to talk about what the next year holds for the NAFLD-metabolic disease link.
In Season 3 Episode 43, first author Naim Alkhouri and last author Mazen Noureddin join the Surfers to discuss their recently published article, Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The theme of the episode is to explore the role of combination agents for NASH therapy over time. This opening conversation focuses on the design and execution of the triple-agent study, and how it may contribute to fibrotic regression.
Naim Alkhouri and Mazen Noureddin join the Surfers to discuss the future role of Combination Agents with NASH therapy, stemming from their recently published article, Safety and efficacy of combination therapy with semaglutide,cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial (JHEP, 2022). The conversation focuses more broadly on the benefits and future of combination therapies for NASH patients.
From February this year, this conversation lead by Louise Campbell explores the need for and value of patient education in the NASH Patient Care process.
Louise Campbell hosts this week’s NASH Tsunami and talks about educating on liver outcomes. Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan provide their thoughts on education and social resources within the framework of developing a NAFLD pathway.
Louise Campbell hosts this week’s NASH Tsunami to talk about patient empowerment with Jörn Schattenberg, Robert Mitchell-Thain, Michelle Clayton and Stephen Callaghan. The group explores measuring pathways and changing healthcare dynamics through digitization and technology.
Louise Campbell hosts this week’s NASH Tsunami while host, Roger Green, finds a new surf vacationing on the Jersey Shore. In this segment, the role of allied health professionals and patient empowerment is discussed in the context of developing a Sustainable Development Goal Framework for NAFLD.
